UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 20, 2018
LANTHEUS HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 001-36569 | 35-2318913 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| 331 Treble Cove Road, North Billerica, MA | 01862 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (978) 671-8001
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
| Item 5.02. | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On August 20, 2018, the Board of Directors of Lantheus Holdings, Inc. (the “Company”) appointed Robert J. Marshall, Jr. as the Chief Financial Officer and Treasurer of the Company and its subsidiaries, effective September 24, 2018. Mr. Marshall is succeeding John W. Crowley in those roles.
Mr. Marshall brings to the Company more than 30 years of finance experience, including in M&A, capital markets and investor relations. Prior to joining the Company, Mr. Marshall spent 16 years with Zimmer Biomet Holdings, Inc. (NYSE: ZBH), a global medical device company with a leading position in musculoskeletal health. He held various senior leadership roles, including Vice President, Investor Relations and Corporate Treasurer, and most recently as Vice President, Americas Finance, for the U.S., Canadian and Latin American commercial markets. Prior to Zimmer Biomet, Bob was employed with Brown & Williamson Tobacco, a subsidiary of British American Tobacco, p.l.c., in Louisville, Kentucky, where he held several positions of increasing responsibility. Mr. Marshall holds a Master of Business Administration degree from Indiana University, South Bend, and a Bachelor of Business Administration in Finance from the University of Notre Dame. Mr. Marshall also holds the CFA designation.
In connection with Mr. Marshall’s appointment as Chief Financial Officer and Treasurer, his annual base salary will be $405,000 and his target annual bonus will be 55% of his annual base salary. Following commencement of his employment, Mr. Marshall will also be granted restricted shares of the Company’s common stock valued at $600,000 in the aggregate (based on the closing price of a share of the Company’s common stock on the grant date), which shares will vest in equal annual installments on each of the first four anniversaries of the grant date. For 2019, he will also have a target long-term equity incentive grant of 125% of his annual base salary.
Mr. Crowley will continue with the Company in a full time advisory role through September 28, 2018 and will work with Mr. Marshall to ensure a smooth transition. The separation with Mr. Crowley is not due to any disagreement with the Company, its Board of Directors, its Audit Committee or its auditors or on any matter relating to the Company’s operations, policies, practices or financial statements, including its controls or other financial related matters.
A copy of the Company’s press release, dated August 20, 2018, announcing the appointment of Mr. Marshall as Chief Financial Officer and Treasurer is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| LANTHEUS HOLDINGS, INC.
| ||
| By: | /s/ Michael P. Duffy | |
| Name: | Michael P. Duffy | |
| Title: | Senior Vice President, Law and Public Policy, General Counsel & Secretary | |
Date: August 20, 2018
Exhibit 99.1
Lantheus Holdings Appoints Robert J. Marshall, Jr. as Chief Financial Officer and Treasurer
NORTH BILLERICA, Mass. (August 20, 2018) – Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced that it has appointed Robert J. Marshall, Jr. as Chief Financial Officer and Treasurer, effective September 24, 2018. Mr. Marshall succeeds Jack Crowley, who will continue with the Company in a full time advisory role until September 28, 2018, and will work with Mr. Marshall to ensure a smooth transition.
Mr. Marshall brings to the Company more than 30 years of finance experience, including in M&A, capital markets and investor relations. Prior to joining the Company, Mr. Marshall spent 16 years with Zimmer Biomet Holdings, Inc. (NYSE: ZBH), a global medical device company with a leading position in musculoskeletal health. He held various senior leadership roles, including Vice President, Investor Relations and Corporate Treasurer, and most recently as Vice President, Americas Finance, for the U.S., Canadian and Latin American commercial markets. Prior to Zimmer Biomet, Bob was employed with Brown & Williamson Tobacco, a subsidiary of British American Tobacco, p.l.c., in Louisville, Kentucky, where he held several positions of increasing responsibility.
“Bob’s financial acumen and extensive experience in M&A, capital markets and investor relations make him an ideal fit as we look to grow our business and deliver long-term sustainable growth and profitability. He has particularly strong transactional expertise, which will be useful as we look to grow both organically and through future potential acquisitions,” said Mary Anne Heino, President and Chief Executive Officer of the Company. “We thank Jack for his valued service to the Company over the past eight years, and we wish him well in his future endeavors.”
Mr. Marshall said, “I am excited to join Lantheus as it enters its next phase of growth. I look forward to working with my new colleagues and employing my experience to help the Company continue its strong performance record, optimize its balance sheet, execute on strategic transactions and commercialize innovative products.”
Mr. Marshall holds a Master of Business Administration degree from Indiana University, South Bend, and a Bachelor of Business Administration in Finance from the University of Notre Dame. Bob also holds the CFA designation.
Mr. Crowley said, “I am thankful for being part of the Lantheus team that has both grown the Company into one of the market leaders it is today and positioned it well for its next stage of growth. I am confident that the Company is in a strong position moving forward.”
About Lantheus Holdings, Inc. and Lantheus Medical Imaging, Inc.
Lantheus Holdings, Inc. is the parent company of LMI, a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products. LMI provides a broad portfolio of products, including the echocardiography contrast agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite® (Technetium Tc99m Generator), a technetium-based
generator that provides the essential medical isotope used in nuclear medicine procedures; and Xenon (Xenon Xe 133 Gas), an inhaled radiopharmaceutical imaging agent used to evaluate pulmonary function and for imaging the lungs. The Company is headquartered in North Billerica, Massachusetts with offices in Puerto Rico and Canada. For more information, visit www.lantheus.com.
CONTACT
Meara Murphy
978-671-8508
Director, Investor Relations and Corporate Communications
Lantheus Holdings, Inc.
Mary Anne Heino
978-671-8608
President and Chief Executive Officer
Lantheus Holdings, Inc.